ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

FTC Seeks Additional Info From Teva, Cephalon Regarding Merger

DOW JONES NEWSWIRES Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) and acquisition target Cephalon Inc. (CEPH) each received a request to provide additional information to the U.S. Federal Trade Commission related to a pending $6.8 billion deal between the firms. Israel-based Teva, which trumped a hostile offer from Valeant Pharmaceuticals International Inc. (VRX) in agreeing to buy Cephalon last month, said it had expected the request. The parties have been cooperating with the FTC staff since shortly after the bid was announced, according to Teva, which said it intends to win clearance "as promptly as possible." Teva on Monday said it continues to expect the deal to be completed in the third quarter, following clearance from U.S. and European regulators, as well as winning approval of Cephalon shareholders. Teva's American depositary shares were recently up 0.4% to $49.35 in after-hours trading. -By John Kell, Dow Jones Newswires; 212-416-2480; john.kell@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
04/07/201403:39:11Meda and Valeant Terminate Joint Ventures
03/13/201417:52:06Anacor Pharmaceuticals Swings to a Profit
01/14/201406:11:37Valeant, Actavis, Mylan Said Interested in Buying Pfizer's Generics...
12/16/201309:15:12U.S. Hot Stocks Futures: Hot Stocks to Watch
12/16/201309:00:06Valeant to Acquire Solta Medical for $250 Million
11/15/201309:18:02OZ Management LP 3Q 13F: Holdings As Of Sep 30 -2-
11/15/201309:18:02OZ Management LP 3Q 13F: Holdings As Of Sep 30
11/15/201309:17:55OZ Management LP 3Q 13F: Largest Sales
11/15/201309:15:02Lone Pine Capital 3Q 13F: Holdings As Of Sep 30
11/15/201309:14:57Lone Pine Capital 3Q 13F: Largest Sales
11/15/201309:13:37Maverick Capital Ltd. 3Q 13F: Holdings As Of Sep 30
11/15/201309:13:37Maverick Capital Ltd. 3Q 13F: Largest Eliminations
11/15/201308:53:17D. E. Shaw & Co. LP 3Q 13F: Holdings As Of Sep 30 -2-
11/15/201308:53:17D. E. Shaw & Co. LP 3Q 13F: Holdings As Of Sep 30
11/15/201308:49:58Viking Global Investors LP 3Q 13F: Largest Sales
11/15/201308:49:57Viking Global Investors LP 3Q 13F: Holdings As Of Sep 30
11/15/201308:47:28ValueAct Capital Management LP 3Q 13F: Holdings As Of Sep 30
11/15/201308:22:24Janus Capital Management 3Q 13F: Holdings As Of -2-
11/15/201308:22:23Janus Capital Management 3Q 13F: Holdings As Of Sep 30
11/15/201308:21:52Janus Capital Management 3Q 13F: Largest Purchases -2-

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad